1. |
Abstracts:the American Society of Nephrology. Chicago, Illinois, December 12-14, 1982[J]. Kidney Int, 1983, 23(1):93-298.
|
2. |
Strippoli GF, Tong A, Johnson D, et al. Antimicrobial agents to prevent peritonitis in peritoneal dialysis:a systematic review of randomized controlled trials[J]. Am J Kidney Dis, 2004, 44(4):591-603.
|
3. |
Peritoneal Dialysis Adequacy Work Group. Clinical practice guidelines for peritoneal dialysis adequacy[J]. Am J Kidney Dis, 2006, 48(Suppl 1):S98-S129.
|
4. |
Piraino B, Bailie GR, Bernardini J, et al. Peritoneal dialysis-related infections recommendations:2005 update[J]. Perit Dial Int, 2005, 25(2):107-131.
|
5. |
Caring for Australians with Renal Impairment (CARI). The CARI guidelines. Evidence for peritonitis treatment and prophylaxis:prophylactic antibiotics for insertion of peritoneal dialysis catheter[J]. Nephrology (Carlton), 2004, 9(Suppl 3):S72-S75.
|
6. |
Strippoli GF, Tong A, Johnson D, et al. Catheter-related interventions to prevent peritonitis in peritoneal dialysis:a systematic review of randomized, controlled trials[J]. J Am Soc Nephrol, 2004, 15(10):2735-2746.
|
7. |
黎伟, 廖蕴华, 薛超, 等. 腹膜透析相关性腹膜炎相关因素分析[J]. 广东医学, 2007, 28(8):1292-1294.
|
8. |
Barbosa D, Lima L, Silbert S, et al. Evaluation of the prevalence and risk factors for colonization by vancomycin-resistant Enterococcus among patients on dialysis[J]. Am J Kidney Dis, 2004, 44(2):337-343.
|
9. |
O'Riordan A, Abraham KA, Ho JK, et al. Vancomycin-resistant Peritonitis associated with peritoneal dialysis:a cause for concern[J]. Ir J Med Sci, 2002, 171(1):42-43.
|
10. |
Passadakis P, Oreopoulos D. The case for oral treatment of peritonitis in continuous ambulatory peritoneal dialysis[J]. Adv Perit Dial, 2001, 17:180-190.
|
11. |
Morse GD, Farolino DF, Apicella MA, et al. Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis[J]. Antimicrob Agents Chemother, 1987, 31(2):173-177.
|
12. |
Tosukhowong T, Eiam-Ong S, Thamutok K, et al. Pharmacokinetics of intraperitoneal cefazolin and gentamicin in empiric therapy of peritonitis in continuous ambulatory peritoneal dialysis patients[J]. Perit Dial Int, 2002, 21(6):587-594.
|
13. |
Bouza P, García Falcón T, Pérez Fontán M, et al. Treatment of CAPD-related peritonitis with ciprofloxacin:results after seven years[J]. Adv Perit Dial, 1996, 12:185-188.
|
14. |
Pérez Fontán M, Rosales M, Rodríguez-Carmona A, et al. Treatment of peritonitis in CAPD with ciprofloxacin:long-term experience[J]. Adv Perit Dial, 1993, 9:211-214.
|
15. |
Van Biesen W, Vanholder R, Vogelaers D, et al. The need for a center-tailored treatment protocol for peritonitis[J]. Perit Dial Int, 1998, 18(3):274-281.
|
16. |
Nye KJ, Gibson SP, Nwosu AC, et al. Single-dose intraperitoneal vancomycin and oral ciprofloxacin for the treatment of peritonitis in CAPD patients:preliminary report[J]. Perit Dial Int, 1993, 13(1):59-60.
|
17. |
Celik A, Cirit M, Tünger A, et al. Treatment of CAPD peritonitis with oral trimethoprim/sulfamethoxazole and intraperitoneal aminoglycoside combination[J]. Perit Dial Int, 1999, 19(3):284-285.
|
18. |
Szeto CC, Chow KM, Kwan BC, et al. Staphylococcus aureus peritonitis complicates peritoneal dialysis:review of 245 consecutive cases[J]. Clin J Am Soc Nephrol, 2007, 2(2):245-251.
|
19. |
郭群英, 陈林, 阳晓, 等. 腹膜透析相关感染性腹膜炎致病菌及菌谱变化——单个腹膜透析中心15年回顾分析[J]. 中华肾脏病杂志, 2006, 22(12):719-724.
|
20. |
Krishnan M, Thodis E, Ikonomopoulos D, et al. Predictors of outcome following bacterial peritonitis in peritoneal dialysis[J]. Perit Dial Int, 2002, 22(5):573-581.
|
21. |
吕鹏. 腹膜透析相关腹膜炎致病菌及耐药性分析(附65例报告)[J]. 中国现代药物应用, 2012, 1(6):82-83.
|
22. |
吴晶晶, 刘佳, 张莉, 等. 腹膜透析相关性腹膜炎致病菌及耐药性分析[J]. 中华医院感染学杂志, 2011, 16(16):3521-3523.
|
23. |
贺全仁, 陈孝治. 耐甲氧西林金葡球菌的药物防治[J]. 国外医药:抗生素分册, 1997, 18(6):442-443, 472.
|
24. |
Krothapalli RK, Senekjian HO, Ayus JC. Efficacy of intravenous vancomycin in the treatment of gram-positive peritonitis in long-term peritoneal dialysis[J]. Am J Med, 1983, 75(2):345-348.
|
25. |
程莉, 候凡凡, 张训, 等. CAPD相关性腹膜硬化[J]. 国外医学:泌尿系统分册, 1996, 16(2):67-70.
|
26. |
Barratt M, Davison AMA, Cameron JS, et al. Oxford textbook of clinical nephrology[M]. Oxford:Oxford University Press, 1992:1477-1505.
|
27. |
Taipale J, Saharinen J, Hedman K, et al. Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfibrils[J]. J Histochem Cytochem, 1996, 44(8):875-889.
|
28. |
田文谋, 于德昌. 腹膜炎[M]. 北京:人民卫生出版社, 1988:8.
|
29. |
Shemin D, Maaz D, St Pierre D, et al. Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients[J]. Am J Kidney Dis, 1999, 34(1):14-20.
|
30. |
白建伟, 晋援朝, 白林, 等. 氟康唑与四种抗生素的配伍和稳定 性[J]. 第四军医大学学报, 2004, 25(12):1140-1142.
|
31. |
牛凤珍, 毕秀云. 可夫新与头孢哌酮钠舒巴坦钠存在配伍禁忌[J]. 临床护理杂志, 2009, 3(3):69.
|
32. |
李健, 周燕文, 马妮飞. 氟罗沙星注射液与4种抗生素配伍的稳定性[J]. 中国医院药学杂志, 2002, 1(1):61-62.
|
33. |
毛文, 周少怀, 柯国平. 加替沙星注射液与4种抗生素配伍的稳定性[J]. 数理医药学杂志, 2007, 4(4):530-531.
|
34. |
陈灏珠. 实用内科学[M]. 11版. 北京:人民卫生出版社, 2002:1789-1791.
|
35. |
郑芝田. 胃肠病学[M]. 3版. 北京:人民卫生出版社, 2000:839-843.
|